Searchable abstracts of presentations at key conferences in endocrinology

ea0085oc7.5 | Oral Communications 7 | BSPED2022

Monogenic obesity is probably not so rare - experience from a large tier 3 paediatric weight management service

Hawton Katherine , Hickingbotham Hannah , Hamilton-Shield Julian , Giri Dinesh

Background: Monogenic obesity is generally considered to only be responsible for a small proportion of genetic obesity with the vast majority attributable to polygenic obesity. Previous studies estimate that monogenic obesity accounts for less than 5% of obesity in Caucasian populations.Aims and method: To identify prevalence and clinical characteristics of monogenic obesity, we reviewed clinical notes of 219 patients currently, or recently (within 24 mo...

ea0058p076 | Diabetes | BSPED2018

Feeding and autoimmunity in down’s syndrome evaluation study (FADES)

Williams Georgina , Mortimer Georgina , Gillespie Kathleen , Hamilton-Shield Julian

Introduction: Children with Down’s Syndrome (DS) have altered immunity with higher rates of diabetes, thyroid autoimmunity, coeliac disease, respiratory tract infections and leukemia. Diabetes in children with DS appears to be accelerated with an earlier age of onset compared with the general population, with 22% diagnosed before the age of 2 years. Increased HLA class II DR3/4 susceptibility is seen in in children with DS and diabetes but the prevalence is reduced compar...

ea0045oc7.1 | Oral Communications 7- Diabetes | BSPED2016

Hypercholesterolaemia screening in type 1 diabetes – a difference of opinion

Candler Toby , Mahmoud Osama , Edge Julie , Hamilton-Shield Julian

Background: The National Institute for Health and Care Excellence (NICE) guidelines on childhood type 1 diabetes (T1D) do not recommend cholesterol screening. However, the National Paediatric Diabetes Audit (NPDA) has an annual cholesterol measure (>12 years) as a key outcome indicator. This is confusing for professionals managing children with T1D.Methods: An online survey was sent to 280 members of the Association of Children’s Diabetes Clinic...

ea0045oc8.6 | Oral Communications 8- Diabetes | BSPED2016

Is abuse associated with adolescent overweight and obesity?: A population cohort study

Hawton Katherine , Norris Tom , Crawley Esther , Hamilton-Shield Julian

Background and Objectives: Abuse in childhood is associated with obesity in adult life. However, little is known about the relationship between abuse and obesity during childhood or adolescence. The aim of this study was to investigate, using a birth cohort study, whether there was an association between pre-adolescent child abuse and overweight and obesity in later childhood. We hypothesised that abuse and obesity may be associated.Methods: Using data f...

ea0095p142 | Obesity 2 | BSPED2023

Immune modulatory response to rituximab in ROHHAD syndrome

Hawton Katherine , Hogan Andrew , Hamilton-Shield Julian , Giri Dinesh

Background: Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation (ROHHAD) is a rare syndrome associated with high morbidity. An immune-inflammatory aetiology has been postulated; however, the immune characteristics and effect of immunomodulation have not been well described.Case report: We describe the immune profile and the effect of rituximab on the immunomodulation potentially ca...

ea0078OC7.1 | Oral Communications 7 | BSPED2021

Utility of glycated haemoglobin in assessing abnormal glucose homeostasis in children and adolescents with obesity undergoing oral glucose tolerance test

Matan Ayaan , Hawton Katherine , Riaz Kulsoom , Shield Julian P H , Candler Toby , Giri Dinesh

Background: Childhood obesity and type 2 diabetes mellitus (T2DM) have increased proportionately in the last decade. Oral glucose tolerance test (OGTT) is recommended for paediatric patients with a BMI >98th centile (NICE, 2014) to identify T2DM or abnormal glucose homeostasis (AGH).Aim: To estimate the proportion of patients with AGH/T2DM seen in a tier 3 obesity service and evaluate the utility of the glycated haemoglobin (HbA1C) in detecting AGH. ...

ea0078p46 | Obesity | BSPED2021

Liraglutide with lifestyle modifications causing rapid weight loss in an adolescent with morbid obesity and life threatening sleep apnoea

Williams Georgina , Easter Shelley , Langton Hewer Simon C , Shield Julian P. H. , Giri Dinesh

Introduction: The management of childhood obesity is complex and requires intensive input from a multidisciplinary team. Pharmaceutical interventions may be required in addition to lifestyle modifications to treat morbid obesity. In a double blind randomised controlled trial, liraglutide, a glucagon-like peptide 1 (GLP-1) agonist along with dietary and lifestyle interventions showed beneficial BMI reduction in children and adolescents. We present a morbidly obese adolescent wi...

ea0085oc3.1 | Oral Communications 3 | BSPED2022

A rare form of ovotesticular difference of sex development (DSD) in combination with severe early-onset obesity due to MC4R mutation: clinical features and diagnostic challenges

Hawton Katherine , Narayan Kruthika , Hamilton-Shield Julian , Giri Dinesh , Crowne Elizabeth

Background: We describe a patient with 46XX ovotesticular difference of sex development (DSD) due to 46XX/69XXY gonadal mixoploidy, also an NR5A1 variant, who developed severe early-onset obesity and subsequently a pathogenic MC4R variant was identified.Case Presentation: A term Caucasian baby weighing 3.64kg with non-consanguineous parents presented with atypical genitalia (Prader Stage 2-3) with clitoromegaly, perineal urethral openin...

ea0085oc9.7 | Oral Communications 9 | BSPED2022

Liraglutide for the treatment of severe obesity in children: early experiences from a tier 3 paediatric weight management service

Hawton Katherine , Price-Drewett Olivia , Wenn Melanie , Fitzgerald Amy , Hamilton-Shield Julian , Giri Dinesh

Background: Liraglutide is a glucagon-like peptide analogue recently approved for use in children and young people for treating obesity. It is recommended for use within multidisciplinary weight management services, alongside dietetic and lifestyle interventions, in children over 12 years with severe obesity.Aim: To describe our experiences of using liraglutide in a tier 3 paediatric obesity service in a patient cohort who had previously failed to succes...

ea0027p79 | (1) | BSPED2011

Clinical characterisation of hyperinsulinaemic hypoglycaemia associated with intra-uterine growth restriction

Kapoor Ritika , Flanagan Sarah , Kumaran Anitha , Shield Julian , Ellard Sian , Hussain Khalid

Background: Intra-uterine growth restriction (IUGR) is a known risk factor for the development of hyperinsulinaemic hypoglycaemia (HH). The phenotype of a large cohort of neonates who develop HH following IUGR has not been studied previously.Aim: To characterise the clinical aspects of a cohort of neonates with IUGR who developed HH.Methodology: Thirty-nine patients with IUGR (defined as birth weight <10th centile) who presente...